Lee Ainslie Esperion Therapeutics, Inc. Call Options Transaction History
Maverick Capital LTD
- $5.17 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ESPR
# of Institutions
215Shares Held
129MCall Options Held
1.78MPut Options Held
1.27M-
Wasatch Advisors Inc Salt Lake City, UT24.5MShares$44.6 Million0.27% of portfolio
-
Black Rock Inc. New York, NY14MShares$25.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$18.1 Million0.44% of portfolio
-
Morgan Stanley New York, NY6.31MShares$11.5 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $121M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...